TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MAIA Biotechnology, Inc. ( (MAIA) ) has shared an announcement.
On November 20, 2025, MAIA Biotechnology announced that its CEO, Vlad Vitoc, presented the efficacy of their telomere-targeting agent, ateganosine, at the Smart Diaspora 2025 conference in Romania. The company has begun enrolling patients in Romania for the Phase 2 THIO-101 Part C study, which evaluates ateganosine as a treatment for advanced non-small cell lung cancer. This expansion aims to accelerate patient access to the therapy and strengthen MAIA’s strategy for accelerated approval in the U.S. The study has shown promising results, with a 38% response rate in third-line NSCLC patients, compared to the current treatment’s response rate of up to 6%.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted immunotherapies for cancer. The company’s lead program involves ateganosine (THIO), a telomere-targeting agent aimed at treating non-small cell lung cancer (NSCLC) in patients with telomerase-positive cancer cells.
Average Trading Volume: 565,932
Technical Sentiment Signal: Sell
Current Market Cap: $34.07M
For detailed information about MAIA stock, go to TipRanks’ Stock Analysis page.